Syros’s AML Failure Sparks MDS Program Jitters, But Fears May Be Overblown

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.

The decision by Syros Pharmaceuticals, Inc. to discontinue enrollment in the Phase II SELECT-AML-1 trial of tamibarotene in newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy has generated concern about potential read-through to its lead program with the drug in higher-risk myelodysplastic syndrome (MDS). However, analysts are still relatively optimistic about the MDS trial’s prospects.

Syros said 12 August that it discontinued enrollment in the AML trial – which compares tamibarotene combined with AbbVie Inc. and 

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By Xu Hu

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

More from Start-Ups & SMEs

Pathalys Raises $105m To Pave Path Toward US Commercialization

 
• By Mandy Jackson

The start-up launched last year with Phase III-ready upacicalcet, which has nearly completed two pivotal trials in secondary hyperparathyroidism and for which it has exclusive rights outside of Asia.

Empress Looks To The Body’s Internal Chemistry For Drug Leads

 
• By Joseph Haas

Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.

Syros’s AML Failure Sparks MDS Program Jitters, But Fears May Be Overblown

 
• By Alaric DeArment

Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.